martes, 3 de diciembre de 2019

Hybridoma cell lines producing antibodies to RSV NS1 | Office of Technology Transfer, NIH

Hybridoma cell lines producing antibodies to RSV NS1 | Office of Technology Transfer, NIH

 logo

Licensing and Collaboration Opportunity
RSV
Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and labeled with anti-RSV F protein/gold antibodies (colorized yellow) shedding from the surface of human lung epithelial A549 cells. Credit: NIAID


Are you investigating respiratory syncytial virus (RSV) infection processes? NIAID researchers have found a new set of hybridoma cell lines that are available for licensing or further development and evaluation under a research collaboration.
These cell lines each express a single monoclonal antibody against RSV nonstructural protein 1 (NS1) and have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist.
Read more about this exciting licensing opportunity: https://www.ott.nih.gov/technology/e-167-2018-0

No hay comentarios:

Publicar un comentario